Regeneron announces regulatory submission in Japan


Bayer (BAYRY) has filed for Japanese approval of Regeneron's (REGN) Eylea therapy for treating patients with diabetic macular edema, the companies have said. Bayer has the rights to sell Eyelea outside the U.S.

The submission is based on Phase 3 clinical trials that proved a statistically significant improvement in best-corrected visual acuity from baseline at 52 weeks compared with laser photcoagulation.

The companies didn't provide a timetable for marketing approval, although the process is usually slower than with the FDA in the U.S. (PR)

From other sites
Comments (1)
  • toosmarttofail
    , contributor
    Comments (697) | Send Message
     
    ACTC's stemcell treatment is going to blow Eylea out of the water and prove a major headache for Bayer.
    5 Mar 2014, 05:15 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs